NCT04933422View on ClinicalTrials.gov

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2027

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Glioblastoma
Interventions
DRUG

CM93

oral capsule of CM93 administered once daily

Sponsors
All Listed Sponsors
lead

Crimson Biopharm Inc.

INDUSTRY